Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Boston Scientific Corporation $BSX is Banque Transatlantique SA's 10th ...

AI-generated analysis

🏦 Banque Transatlantique SA increased its BSX holdings by 13.0% in Q4, adding 139,431 shares for a total value of $115.46 million.

πŸ“ˆ Ieq Capital LLC significantly boosted its stake by 97.0%, now owning 123,592 shares valued at $13.28 million.

πŸ’Ό Director Edward J. Ludwig purchased 3,580 shares on May 20th for a total of $202,914.40.

πŸ“Š Q1 earnings beat expectations with $0.80 EPS versus the $0.79 consensus estimate.

πŸ’° Revenue reached $5.20 billion, marking an 11.6% increase compared to the previous year.

πŸ”„ The company authorized a new $5.00 billion share buyback program approved on May 18th.

πŸ“‰ Leerink Partners lowered its price target to $74.00 while maintaining an 'outperform' rating.

πŸ“‰ Barclays reduced its price objective to $89.00 with an 'overweight' rating.

πŸ“ˆ Goldman Sachs set a price target of $71.00 in a research note released on May 28th.

πŸ₯ Boston Scientific focuses on less-invasive procedures for cardiovascular, digestive, and urologic conditions.

πŸ“‰ Weiss Ratings downgraded the stock from 'hold (c)' to 'hold (c-)' on May 13th.

🎯 The consensus analyst price target is currently set at $85.08.

Bullish Signals
  • The company reported a solid earnings beat with $0.80 EPS, exceeding the consensus estimate of $0.79 by $0.01.
  • Revenue grew to $5.20 billion, representing an 11.6% year-over-year increase driven by strong performance.
  • The board initiated a substantial $5.00 billion share buyback program, signaling management confidence in the stock's value.
  • Insiders have been net buyers over the last 90 days, acquiring 9,800 shares worth $554,012.
  • Major institutional investors like Banque Transatlantique SA and Ieq Capital LLC are significantly increasing their positions.
  • The company maintains a strong Return on Equity of 19.17% and a healthy net margin of 17.29%.
Risk Factors
  • Barcls reduced its price objective from $96.00 to $89.00, suggesting a more cautious outlook.
  • Weiss Ratings downgraded the stock from 'hold (c)' to 'hold (c-)', reflecting some analyst concern.
  • Goldman Sachs set a lower price target of $71.00 compared to previous higher valuations.
Full Analysis
Banque Transatlantique SA increased its stake in Boston Scientific Corporation (NYSE:BSX) by 13.0% during the fourth quarter, purchasing an additional 139,431 shares to own a total of 1,211,331 shares valued at $115.46 million. This position represents 2.8% of the bank's portfolio and marks it as the institution's 10th largest holding. Other institutional investors also adjusted their positions, with Ieq Capital LLC increasing its stake by 97.0% to own 123,592 shares worth $13.28 million, while Main Street Financial Solutions LLC grew its holdings by 35.3%. In insider trading activity, Director Edward J. Ludwig purchased 3,580 shares at an average price of $56.68 per share on May 20th, increasing his total ownership to 25,359 shares valued at approximately $1.44 million. Director Cheryl Pegus also acquired 1,770 shares at $56.49 per share. Over the last 90 days, insiders have collectively acquired 9,800 shares worth $554,012, though they still own only 0.34% of the company's total stock. Financially, Boston Scientific reported Q1 earnings of $0.80 per share, beating the consensus estimate of $0.79, with revenue reaching $5.20 billion, an 11.6% year-over-year increase. The company provided guidance for Q2 2026 EPS between $0.82 and $0.84, and full-year FY 2026 EPS between $3.34 and $3.41. Additionally, the board initiated a new share buyback program authorizing the repurchase of up to $5.00 billion in shares, representing up to 6.4% of its outstanding stock. Analyst sentiment remains mixed with recent price target adjustments. Leerink Partners lowered its target from $87.00 to $74.00 while maintaining an 'outperform' rating, and Barclays reduced its objective from $96.00 to $89.00 with an 'overweight' rating. Goldman Sachs set a $71.00 target, and Raymond James lowered its target to $88.00 but kept an 'outperform' rating. The consensus price target stands at $85.08 based on 29 analyst ratings, predominantly 'Buy' or 'Strong Buy', though Weiss Ratings downgraded the stock to a 'hold (c-)'.